Showing results (41-50 of 4,847) with videos related to

Sort By:
Pageof 485
Regulatory Toxicology and Pharmacology : RTP|January 22, 2021
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studiesPaul Baldrick, Andreas Reichl
Regulatory Toxicology and Pharmacology : RTP|January 23, 2021
Human biomonitoring (HBM)-II values for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) - Description, derivation and discussionMichael Schümann, Hellmuth Lilienthal, Jürgen Hölzer
Regulatory Toxicology and Pharmacology : RTP|January 25, 2021
Mercury in skin-care products in India and consumer exposure risksSupriti Pramanik, Mukesh Kumar, Asif Qureshi
Regulatory Toxicology and Pharmacology : RTP|January 15, 2021
Compounded conservatism in European re-entry worker risk assessment of pesticidesFelix M Kluxen, Edgars Felkers, Jenny Baumann, et al.
Regulatory Toxicology and Pharmacology : RTP|December 10, 2021
PDE concept for controlling cleaning agent residues in pharmaceuticals- A critical analysisS Araya, T Pfister, K Gromek, et al.
Regulatory Toxicology and Pharmacology : RTP|January 10, 2022
Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in ratsXiaobo Li, Xingcheng Liao, Xiufang Yan, et al.
Regulatory Toxicology and Pharmacology : RTP|January 6, 2022
A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessmentCamilla Alexander-White, Dagmar Bury, Mark Cronin, et al.
Regulatory Toxicology and Pharmacology : RTP|May 7, 2008
28-Day repeated dose oral toxicity of recombinant human apo-lactoferrin or recombinant human lysozyme in ratsD Cerven, G DeGeorge, D Bethell
Regulatory Toxicology and Pharmacology : RTP|March 26, 2014
Current modeling practice may lead to falsely high benchmark dose estimatesJoakim Ringblom, Gunnar Johanson, Mattias Öberg
Pageof 485